In 2021, Interim data from the OlympiA study were released, which suggesting that one-year adjuvant therapy with Olaparib alone can obviously reduce the risk of recurrence and death in HER2-negative early-stage breast cancer patients with gBRCA mutation (55). Here, ERBB2 is linked to breast carcinoma.